Table 18. Concomitant Use of Selected Antiretroviral Drugs and Hepatitis C Virus Direct-Acting Antiviral Drugs for Treatment of Hepatitis C Virus in Adults with HIV

Body
Table 18. Concomitant Use of Selected Antiretroviral Drugs and Hepatitis C Virus Direct-Acting Antiviral Drugs for Treatment of Hepatitis C Virus in Adults with HIV
Selected HIV Drugs HCV Direct-Acting Antiviral Agents
Individual Drugs Coformulated
 

SHOULD NOT BE USED IN THOSE WITH MODERATE TO SEVERE HEPATIC IMPAIRMENT

(Cirrhosis classified as Child-Pugh class B or C)

Daclatasvir Sofosbuvir Ledipasvir/
Sofosbuvir
Sofosbuvir/
Velpatasvir
Sofosbuvir/
Velpatasvir/
Voxilaprevir
Glecaprevir/
Pibrentasvir
Elbasvir/
Grazoprevir
Ombitasvir/
Paritaprevir/
RTV plus Dasabuvira
NRTIs

3TC

ABC

FTC

TAF

TDF

Monitor for TDF-associated adverse events.

Monitor for TDF-associated adverse events.

Monitor for TDF-associated adverse events.

PIs

Unboosted ATV

X

X

X

b

ATV/r or ATV/c

daclatasvir dose to 30 mg/day

If a PI/r or PI/c is used with TDF, ↑ TDF concentrations are expected. If coadministration is necessary, monitor for TDF-associated adverse events.d

If a PI/r or PI/c is used with TDF, ↑ TDF concentrations are expected. If coadministration is necessary, monitor for TDF-associated adverse events.d

X

X

X

c

DRV/r or DRV/c

If a PI/r is used with TDF, ↑ TDF concentrations are expected. Monitor for TDF-associated adverse events.d Consider monitoring for hepatotoxicity.e

X

X

X

LPV/r

X

X

X

X

TPV/r

?

X

 

X

X

X

X

X

NNRTIs

DOR

If used with TDF, monitor for TDF-associated adverse events.

EFV

↑ daclatasvir dose to 90 mg/day

X

X

X

X

X

ETR

↑ daclatasvir dose to 90 mg/day

X

X

X

X

X

NVP

↑ daclatasvir dose to 90 mg/day

X

X

X

X

X

RPV PO and IM

X

INSTIs

BIC/TAF/FTC

CAB PO and IM

X

Potential for QT interval prolongation with higher RPV concentrations.

RPV is copackaged and coadministered with CAB IM.

DTG

If used with TDF, monitor for TDF-associated adverse events.

EVG/c/TDF/FTC

↓ daclatasvir dose to 30 mg/day

X

If used with TDF, monitor for TDF-associated adverse events.

If used with TDF, monitor for TDF-associated adverse events. Consider monitoring for hepatotoxicity.e

If used with TDF, monitor for TDF-associated adverse events. Consider monitoring for hepatotoxicity.f

X

X

EVG/c/TAF/FTC

↓ daclatasvir dose to 30 mg/day

Consider monitoring for hepatotoxicity.e

Consider monitoring for hepatotoxicity.f

X

X

RAL

CCR5 Antagonist

MVC

X

Attachment Inhibitor

FTR

X

Use alternative HCV regimen if possible.

X

Use alternative HCV regimen if possible.

a Dasabuvir must be prescribed with ombitasvir/paritaprevir/RTV.

b Reduce ATV dose to 300 mg and instruct the patient to take it in the morning at the same time as ombitasvir/paritaprevir/RTV plus dasabuvir. If RTV cannot be used, choose an alternative HCV regimen.

c This HCV regimen contains RTV. If ATV is part of the ARV regimen, prescribe ATV 300 mg without COBI or RTV. The modified ARV regimen should be taken in the morning at the same time as ombitasvir/paritaprevir/RTV plus dasabuvir. Resume RTV or COBI regimen when HCV therapy is completed.

d Consider using an alternative HCV treatment or ARV regimen to avoid increases in TDF exposure. If coadministration is necessary, monitor patient for TDF-associated adverse events.

e Voxilaprevir exposures can increase when it is coadministered with pharmacologically boosted DRV or EVG. Until more safety data in clinical settings become available, patients who are receiving voxilaprevir and pharmacologically boosted DRV or EVG should be monitored for hepatotoxicity.

f Glecaprevir exposures can increase when it is coadministered with EVG/c. Until more safety data in clinical settings become available, patients who are receiving glecaprevir and EVG/c should be monitored for hepatotoxicity.

 

Key to Symbols:

√ = ARV agents that can be used concomitantly
X = ARV agents not recommended
? = Data on PK interactions with ARV drug are limited or not available
↑ = Increase
↓ = Decrease

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; BIC = bictegravir; CAB = cabotegravir; CCR5 = C-C chemokine receptor type 5; COBI = cobicistat; DAA = direct-acting antiviral; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; FTR = fostemsavir; HCV = hepatitis C virus; IM = intramuscular; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PI/c = protease inhibitor/cobicistat; PI/r = protease inhibitor/ritonavir; PK = pharmacokinetic; PO = oral; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TPV/r = tipranavir/ritonavir

 

References